Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 9Terminated 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 31Lymphoma 19Neoplasms, Plasma Cell 16Myelodysplastic Syndromes 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 13Leukemia, Myeloid, Acute 13Leukemia 13Hodgkin Disease 12Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Retinoblastoma 6Lymphoma, Mantle-Cell 6Burkitt Lymphoma 6Myeloproliferative Disorders 5Immunoglobulin Light-chain Amyloidosis 5Recurrence 4Primary Myelofibrosis 4Ovarian Neoplasms 4Neuroblastoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Neoplasms 4Congenital Abnormalities 4Sezary Syndrome 3Myelodysplastic-Myeloproliferative Diseases 3

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Melphalan × Clear all
NCT02366663 2018-03-12

SPINOZA

City of Hope Medical Center

Phase 3 Terminated
3 enrolled 8 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00793650 2012-08-30

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

Emory University

Phase 1/2 Terminated
39 enrolled 9 charts
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡